Annotation of rs11280056

Genotypes TTAAAGTTA/del + del/del are not associated with response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotype del/del.

No significant association with response, progression-free survival or overall survival was found for this variant. This variant was originally mapped to rs151264360, which has been merged into rs11280056. This annotation replaces VA 1448568367.

From Publication

Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies. The pharmacogenomics journal. 2017. Meulendijks D et al.
PMID:27995989(opens in new window) DOI:10.1038/tpj.2016.81(opens in new window)

Gene

TYMS

Variant

rs11280056

Phenotype Category

Efficacy

Association Significance

The study reports this association is not significant

PharmGKB ID

1450821655

Score
More info on scoring

-1.5

Evidence for Clinical Annotations

This annotation has been used as evidence for the following clinical annotations.

    Study Parameters

    Study type

    cohort

    Study size

    185

    Association p-value

    > 0.05

    Population description

    Drug: 1) Capecitabine + epirubicin + cisplatin (ECC) or 2) Capecitabine + docetaxel + oxaliplatin (DOC) or 3) DOC + bevacizumab (B-DOC) or 4) B-DOC + trastuzumab.

    Note: Alleles in PharmGKB are mapped to the positive chromosomal strand. Therefore, variants in genes on the "minus" strand (eg. VKORC1) are complemented in PharmGKB annotations.

    History

    No history available.